ArticleEuropean thyroid journal2026
Hypercalcitoninemia in chronic kidney disease: an old issue, a new perspective?
Article in European thyroid journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Chronic kidney disease (CKD) has been reported in association with hypercalcitoninemia, but the calcitonin (Ct) values to expect in CKD patients are unknown. This study aimed to evaluate Ct levels in CKD patients using an accurate chemiluminescent immunoassay. Methods: Two population datasets were analyzed: Group 1 consisted of 9,450 anonymous subjects with Ct and creatinine measurements; this group was subdivided according to eGFR into a control series (eGFR ≥ 90 mL/min/1.73 m2, n = 4,294) and a CKD series (eGFR < 90 mL/min/1.73 m2, n = 4,022). Group 2 consisted of 135 patients with CKD (78.5% in stage 5). Renal function and Ct levels were retrospectively evaluated. Results: The Group 1 CKD series had a median Ct of 1.0 ng/L (IQR: 1.0-2.8 ng/L), 181 patients (4.5%) had Ct > 10 ng/L and ≤30 ng/L, and 35 patients (0.9%) had Ct ≥ 30 ng/L. Median Ct differed significantly according to CKD stage: 1.00 ng/L (IQR: 1.00-2.40 ng/L) in stage 2; 1.20 ng/L (IQR: 1.00-4.30 ng/L) in stage 3; 2.80 ng/L (IQR: 1.00-6.75 ng/L) in stage 4; and 4.55 ng/L (IQR: 1.00-11.30 ng/L) in stage 5 (P < 0.001). Median Ct in the control series was 1.0 ng/L (IQR: 1.0-2.9 ng/L). Ct levels >10 ng/L were significantly associated with CKD stage and were observed in 16.7% of stage 4 patients and 31.1% of stage 5 patients vs 4.3% of controls (P < 0.001). In Group 1, Ct levels were significantly correlated with creatinine (P < 0.001). In Group 2, median Ct was 3.7 ng/L (IQR: 1.0-7.0 ng/L), 25 patients (18.5%) had Ct levels >10 ng/L, and Ct levels were not associated with renal function. Conclusions: Ct levels may be mildly elevated in advanced CKD; until stage 3, the increase is negligible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.